Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics, with news centered on its approved medicines, TTR franchise, clinical pipeline and financial performance. Company updates commonly address AMVUTTRA/vutrisiran and ONPATTRO/patisiran for transthyretin-mediated amyloidosis, GIVLAARI/givosiran for acute hepatic porphyria, OXLUMO/lumasiran for primary hyperoxaluria type 1, and partner-commercialized RNAi medicines.
Recurring developments include quarterly product revenue reports, guidance, clinical and real-world data for ATTR-CM and other cardiovascular programs, pipeline progress across cardio-metabolic disease, neuroscience and hematology, disease-awareness collaborations, and investor conference presentations. Alnylam also reports on its Alnylam 2030 strategy and commercialization of RNAi medicines in global markets.
Alnylam (Nasdaq: ALNY) will present a company overview at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET. A live audio webcast will be available on the company investor site and a replay will be posted within 48 hours.
Alnylam (Nasdaq: ALNY) reported Q4 2025 global net product revenues of $995 million and full‑year 2025 net product revenues of $2,987 million, representing 121% and 81% growth versus 2024. The company achieved GAAP and non‑GAAP profitability for 2025 and outlined its Alnylam 2030 five‑year strategy and 2026 pipeline goals.
Key drivers included the U.S. approval and launch of AMVUTTRA for ATTR‑CM, strong royalties from Leqvio sales, a planned $250 million investment in a proprietary enzymatic‑ligation manufacturing facility, and multiple upcoming clinical readouts in 2026.
Alnylam (Nasdaq: ALNY) will report fourth quarter and full-year 2025 financial results on Thursday, February 12, 2026, before U.S. markets open. Management will host a conference call and live audio webcast at 8:30 AM ET to discuss results and expectations. An archived webcast will be posted about two hours after the event.
Alnylam (Nasdaq: ALNY) reported preliminary full year 2025 net product revenues of $2,987M (81% growth vs. 2024), driven by preliminary total TTR revenues of $2,487M (103% growth). The company provided 2026 combined net product revenue guidance of $4,900M–$5,300M (midpoint ~71% growth), led by Total TTR guidance of $4,400M–$4,700M. New five-year strategy Alnylam 2030 targets TTR leadership, launch of nucresiran in polyneuropathy by 2028 and cardiomyopathy by 2030, 2+ new transformative medicines, expansion to 10 tissue types and >40 programs, ~30% of revenues invested in non-GAAP R&D, 25%+ total revenue CAGR to 2030 and ~30% non-GAAP operating margin.
Alnylam (Nasdaq: ALNY) will present a company overview and host a Q&A at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco.
The company said it will unveil a new five-year strategy, provide an update on unaudited Q4 and full-year 2025 global net product revenues, and give an outlook for 2026 product sales. A live audio webcast and Q&A will be available on Alnylam's investor events page and a replay will be posted within 48 hours after the event.
Alnylam (Nasdaq: ALNY) will invest $250 million to expand its 200,000 sq. ft. Norton, Massachusetts manufacturing site to add a proprietary, scalable siRNA enzymatic-ligation platform, siRELIS™. The expansion is intended to increase capacity, lower production costs, and produce clinical and commercial siRNA drug substance for programs including zilebesiran and nucresiran.
The siRELIS™ platform has been accepted into the FDA Emerging Technology Program to accelerate regulatory engagement. Construction is underway and new capabilities are expected to be fully operational by late 2027.
Alnylam (Nasdaq: ALNY) said it entered private repurchase agreements to buy approximately $34.4 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2027 for a total cash repurchase cost of about $51.9 million including accrued interest.
The final cash price is subject to adjustment based in part on the daily volume-weighted average price of Alnylam common stock during a measurement period beginning December 11, 2025. The repurchases are expected to close shortly after that measurement period, subject to customary closing conditions.
After the transactions close, approximately $362.8 million aggregate principal amount of the Notes will remain outstanding, and previously entered capped call transactions are expected to remain in effect.
Alnylam (Nasdaq: ALNY) reported post hoc analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) showing reductions in gastrointestinal (GI) adverse events and reinforcing monotherapy efficacy.
Key findings: a 42% lower GI event rate overall, 37% lower in vutrisiran monotherapy, and 49% lower in patients on tafamidis at baseline; individual symptoms (diarrhea, nausea, vomiting) fell >50% with rate ratios as low as 0.16. A censored monotherapy analysis showed a 32% reduction in the primary composite endpoint through 36 months (HR 0.68; 95% CI 0.49–0.95; p=0.022), consistent with the primary monotherapy HR 0.67 (p=0.016). AMVUTTRA has >8,000 patient‑years exposure and recent approvals in multiple regions.
Alnylam (Nasdaq: ALNY) announced Board changes effective December 2, 2025 and January 5, 2026.
Two directors departed: Mike Bonney stepped down after serving on the Board since 2014 and holding Board Chair roles from December 2015 to August 2021 and Executive Chair from August 2021 to January 2023; Carolyn Bertozzi, Ph.D., resigned from the Board after joining in 2023 and will continue as a scientific advisor following her election to the Eli Lilly board effective December 8, 2025.
New appointment: Stuart Arbuckle will join as an independent director on January 5, 2026; he spent 13 years at Vertex with senior commercial and operating responsibilities and currently serves on the Rhythm Pharmaceuticals board.
Alnylam (Nasdaq: ALNY) presented post hoc HELIOS-B analyses at AHA 2025 showing vutrisiran improved cardiac structure and function and preserved renal function in ATTR-CM patients.
Key imaging findings: CMR showed amyloid regression in 22% of treated patients vs 0% placebo at Year 3; mean ECV change was -0.10% with vutrisiran vs +7.86% with placebo (p=0.006). Renal results: fewer patients had ≥40% eGFR decline (12.7% vs 21.2%) and treatment reduced risk of death and CV events in patients progressing to CKD stage 4+ (HR 0.47; 95% CI 0.26–0.85).